9-α-substituted estratrienes as selectively active estrogens
First Claim
1. A 9α
- -Substituted estra-1,3,5(10)-triene compound of formula I
4 Assignments
0 Petitions
Accused Products
Abstract
This invention describes the new 9α-substituted estratrienes of general formula I
in which R3, R7, R7′, R13, R16 as well as R17 and R17′ have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.
The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
-
Citations
26 Claims
-
1. A 9α
- -Substituted estra-1,3,5(10)-triene compound of formula I
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
Specification